Glycopeptides - ProtoKinetix

Drug Profile

Glycopeptides - ProtoKinetix

Alternative Names: AAGP™ molecules; PKX-001

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
  • Developer Imaginative Research Associates; ProtoKinetix; ProtoKinetix - Imaginative Research Associates (JV); University of Alberta; University of British Columbia
  • Class Glycopeptides; Glycoproteins; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Macular degeneration; Ocular inflammation
  • Research Inflammation; Skin disorders

Most Recent Events

  • 07 Feb 2017 Preclinical trials in Macular degeneration in Canada (unspecified route) before Feruary 2017
  • 17 Jan 2017 University of Alberta submits Investigational Testing Authorization (ITA) to Health Canada for Type-1 diabetes mellitus
  • 07 Jun 2016 Early research in Neurological disorders in Canada (unspecified route) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top